The crucial data readouts coming soon for small biotechs
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Will Novo’s big thinking in obesity pay off?
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
Will pending clinical readouts make it across the line?
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
Novo bids for recognition in the year of Nash
Having eschewed any late-stage moves in Nash, Novo Nordisk needs its established diabetes drug Ozempic to prove it has a place in the liver disease.
Lilly spends big on mirikizumab
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
Another chance for Lilly and Roche to take on Alzheimer's
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
Novo Nordisk’s quiet entry into the year of Alzheimer’s
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
The joker in Exelixis and Bristol’s kidney cancer pack
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
The first test of Spectrum’s shift
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
